Foundayo

Foundayo is the brand name for orforglipron, an oral GLP-1 receptor agonist developed by Eli Lilly, intended for adults with obesity, or with excess weight and weight-related medical problems, alongside diet and exercise. Unlike Lilly's injectable tirzepatide products (Mounjaro, Zepbound), orforglipron is a single-pathway GLP-1 agonist taken as a once-daily pill rather than a weekly injection — notable because most GLP-1-class medications to date have required injection.